Biovail Corporation, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products used in the treatment of specialty central nervous system disorders. Its product portfolio includes Wellbutrin XL for the treatment of depression in adults; Xenazine for the treatment of chorea associated with Huntington's disease; Aplenzin for the treatment of major depressive disorder; Zovirax Ointment for the management of initial genital herpes; Zovirax Cream for the treatment of herpes labialis; Ultram ER for the management of chronic pain in adults; and Cardizem LA that provides blood pressure control. The company also provides Tiazac/Tiazac XC for the treatment of hypertension and angina; Wellbutrin SR for the treatment of depression; Glumetza for the control of hyperglycemia in adult patients with type 2 diabetes; Ralivia for the management of pain of moderate severity; Nitoman for the treatment of hyperkinetic movement disorders; Cardizem CD medications in the calcium channel blocker category of cardiovascular drugs; and Zyban for smoking cessation treatment. In addition, it distributes various other pharmaceutical products, including Ativan for the management of anxiety disorders; Vasotec and Vaseretic for the treatment of hypertension, symptomatic congestive heart failure, and asymptomatic left ventricular dysfunction; and Isordil to treat prophylaxis of ischemic heart pain associated with coronary insufficiency. The company’s generic products consist of bioequivalent formulations of Cardizem CD, Adalat CC, Procardia XL, Tiazac, Voltaren XR, and Trental. In addition, it offers research, development, and clinical contract research services to third parties. The company distributes its products primarily through third party commercialization relationships in the United States and Canada. Biovail Corporation was founded in 1983 and is headquartered in Mississauga, Canada.

Hospira, Inc., a specialty pharmaceutical and medication delivery company, develops, manufactures, and markets pharmaceuticals and medication delivery systems in the United States and internationally. It offers generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems for hospitals, wholesalers, integrated delivery networks, and alternate site providers, such as clinics, home healthcare providers, and long-term care facilities. The company primarily provides specialty injectable pharmaceutical products that consist of generic injectable pharmaceuticals for analgesia, anesthesia, anti-infective, cardiovascular, and oncology therapeutic areas, as well as Precedex (dexmedetomidine HCl), a proprietary sedative. Its proprietary drug delivery options include Carpuject and iSecure prefilled syringes, Ansyr prefilled needleless emergency syringe systems, First Choice ready-to-use premixed formulations, and the ADD-Vantage System for preparing drug solutions from prepackaged drug powders or concentrates. The company also offers infusion therapy solutions and supplies that include I.V. solutions for general use; and I.V. nutrition products and solutions for the washing and cleansing of wounds or surgical sites. In addition, it provides medication management systems that include electronic drug delivery pumps, safety software, and administration sets that are used to deliver I.V. fluids and medications. Further, the company offers gravity administration sets, formulation development, and injectable and oral drug filling and finishing services. Hospira, Inc. was founded in 2003 and is headquartered in Lake Forest, Illinois.